Acquisition Potential Carmot Therapeutics was recently acquired by Morningstar, showcasing an openness to strategic partnerships and potential future acquisitions.

Public Offering Carmot Therapeutics went public and announced an IPO, indicating opportunities for investment and collaboration with public markets.

Launch of Clinical Trials Carmot Therapeutics launched phase 2 trials for innovative products, presenting a chance for collaboration in clinical research and drug development.

Key Leadership Appointment Carmot appointed Michael Gray as COO and CFO, suggesting potential for new strategic directions and business initiatives under his leadership.

Market Valuation Carmot's potential IPO or sale discussions at a valuation of at least $1B indicate significant market value, making them an attractive potential partner.